Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.